Using disease-free survival as a marker for clinical outcome, this group evaluated the ability of GGH, emmprin, survivin, and DBI expression in tumor tissue to stratify 27 patients treated with neoadjuvant MVAC. The gene discussed is BIRC5; the disease is neoplasm.